Oramed Pharmaceuticals

Oramed enrolls first patient in glucose clamp study for oral insulin

Friday, April 3, 2015 10:22 AM

Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, has enrolled the first patient in its glucose clamp study. The study will be performed at the University of Texas Health Science Center at San Antonio and University Health System's Texas Diabetes Institute under the supervision of Professor Ralph DeFronzo.

More... »

Quest Diagnostics

Oramed appoints Hexter as COO, vice president of business development

Monday, April 22, 2013 08:00 AM

Oramed Pharmaeuticals, a developer of oral drug delivery systems, has appointed Joshua Hexter as chief operating officer and vice president of business development.

More... »


Oramed, Medpace to collaborate on phase II trial

Monday, October 15, 2012 11:54 AM

Oramed, a subsidiary of Jerusalem-based Oramed Pharmaceuticals, a developer of oral drug delivery systems, has retained Medpace as CRO for Oramed's upcoming phase II clinical trial on its oral insulin capsule, ORMD-0801.

More... »

Oramed Pharma, Medpace collaborate on phase II FDA trial of oral insulin

Wednesday, October 3, 2012 10:19 AM

Oramed Ltd., a subsidiary of Oramed Pharmaceuticals, a developer of oral drug delivery systems, has signed an agreement to retain Medpace as a full-service CRO for Oramed's upcoming phase II clinical trial on its oral insulin capsule, ORMD-0801.

More... »

Oramed granted Australian patent for core technology

Thursday, January 26, 2012 09:10 AM

Marking a major milestone for the company, Oramed Pharmaceuticals, a developer of oral drug delivery systems, has received approval for a key patent by the Australian Patent Office. The patent covers an important part of Oramed's core technology, which allows for the oral delivery of peptides.

More... »

Oramed completes toxicity trial for ORMD-0801

Thursday, March 24, 2011 12:33 PM

Oramed Pharmaceuticals, a developer of oral delivery systems, successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801. The study was completed under conditions prescribed by the FDA’s Good Laboratory Practices regulations and is the last study required before an IND filing.

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs